Key result
Familial hypercholesterolemia was not associated with significant differences in complete blood count-derived inflammatory markers compared to non-FH hyperlipidemia, though platelet count was higher (240.43 vs 228.52, p=0.049).
Why the study?
Blood inflammatory markers may be disrupted in patients with familial hypercholesterolemia, but the extent of this disruption remains unclear.
Are hematological inflammatory markers significantly different in patients with familial hypercholesterolemia compared to those with non-FH hyperlipidemia?
Case-Control (n=591)
No
Are hematological inflammatory markers significantly different in patients with familial hypercholesterolemia compared to those with non-FH hyperlipidemia?
Absolute Event Rate: 240.43% vs 228.52%
p-value: p=0.049
CBC-derived inflammatory markers do not significantly differ between FH and non-FH hyperlipidemia patients, though platelet-to-lymphocyte ratio (PLR) is independently associated with total cholesterol levels.
CBC inflammatory markers should not yet differentiate FH from other hyperlipidemia; leaves open any residual platelet signal for prospective confirmation.
Background and aims: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder of lipid metabolism which leads to premature cardiovascular diseases. In patients with FH, blood inflammatory markers may be disrupted; however, its extent is unclear. In this study we aimed to evaluate, the NLR: Neutrophil to lymphocyte ratio, PLR: Platelet count to lymphocyte count ratio, MPV: Mean platelet volume, RPR: Red blood cell distribution width to platelet count ratio, WBC: White blood cell, PDW: Platelet distribution width and platelets count. Methods :The study group consisted of 331 patients with FH and 260 control patients. Controls had a history of hyperlipidemia and both groups could be on pharmacotherapy or not. Results: None of the CBC inflammatory markers were not significantly difference in patients with FH than non-FH. Platelet count was significantly higher among patients with FH when compared to control patients (240.43±54.15 vs 228.52±47.37 p= 0.049*). When we used linear regression analysis, only RLR was independently associated with total cholesterol (b=0.000, p=0.13). Here we showed that CBC markers are nor different between FH and non-FH patients, however PLR is associated with cholesterol level not FH. Conclusions: Our results may show the important of high cholesterol on platelets activity and highlight the use of lipid lowering drugs in patients with hyperlipidemia.
No takes yet. Share an insight, caveat, or question.
Vaseghi et al. (2020) conducted a case-control in Familial hypercholesterolemia (n=591). Familial hypercholesterolemia vs. Non-FH hyperlipidemia was evaluated on Platelet count (p=0.049). Familial hypercholesterolemia was not associated with significant differences in complete blood count-derived inflammatory markers compared to non-FH hyperlipidemia, though platelet count was higher (240.43 vs 228.52, p=0.049).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: